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Epigenome-wide Analysis Identifies
Genes and Pathways Linked to
Neurobehavioral Variation in
Preterm Infants
Todd M. Everson1, Carmen J. Marsit1, T. Michael O’Shea2, Amber Burt 1, Karen Hermetz1,
Brian S. Carter3, Jennifer Helderman4, Julie A. Hofheimer2, Elisabeth C. McGowan5,
Charles R. Neal6, Steven L. Pastyrnak7, Lynne M. Smith8, Antoine Soliman 9,
Sheri A. DellaGrotta10, Lynne M. Dansereau10, James F. Padbury5 & Barry M. Lester5,10,11
Neonatal molecular biomarkers of neurobehavioral responses (measures of brain-behavior
relationships), when combined with neurobehavioral performance measures, could lead to better
predictions of long-term developmental outcomes. To this end, we examined whether variability in
buccal cell DNA methylation (DNAm) associated with neurobehavioral profiles in a cohort of infants
born less than 30 weeks postmenstrual age (PMA) and participating in the Neonatal Neurobehavior
and Outcomes in Very Preterm Infants (NOVI) Study (N = 536). We tested whether epigenetic age, age
acceleration, or DNAm levels at individual loci differed between infants based on their NICU Network
Neurobehavioral Scale (NNNS) profile classifications. We adjusted for recruitment site, infant sex, PMA,
and tissue heterogeneity. Infants with an optimally well-regulated NNNS profile had older epigenetic
age compared to other NOVI infants (β1 = 0.201, p-value = 0.026), but no significant difference in age
acceleration. In contrast, infants with an atypical NNNS profile had differential methylation at 29 CpG
sites (FDR < 10%). Some of the genes annotated to these CpGs included PLA2G4E, TRIM9, GRIK3, and
MACROD2, which have previously been associated with neurological structure and function, or with
neurobehavioral disorders. These findings contribute to the existing evidence that neonatal epigenetic
variations may be informative for infant neurobehavior.
Preterm birth is a significant global public health problem. In the United States one in eight children are born less
than 37 weeks of gestation1. Survival of infants born very preterm, prior to 30 weeks postmenstrual age (PMA),
has improved due to technological and medical advancements2,3. These youngest infants are more likely to suffer
from chronic illnesses, potentially devastating brain injuries, and adverse neuromotor, cognitive, and behavioral outcomes that persist through adulthood4–15. These consequences of premature birth often require extensive
healthcare, educational and psychosocial community resources, in addition to increased burden on the families
and caregivers of these children, emotionally and financially.
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In addition to immaturity, premature infants vary widely in the health complications they experience. As such,
assessments prior to discharge from the neonatal intensive care unit (NICU) are needed to identify the earliest
risks for adverse neurodevelopmental outcomes, and to maximize the potential benefits of interventions aimed
at ameliorating long term deficits. There is growing evidence that neonatal neurobehavior (the relationships
between the nervous system and behavior), as measured by the NICU Network Neurobehavioral Scale (NNNS)16,
predicts developmental deficits in infants born preterm and others at risk, beyond what can be predicted based
on the assessment of medical risk factors throughout the newborn’s hospital stay17–20. Latent profiles of NNNS
summary scores have been used to classify infants into groups with similar responses across the overall NNNS
assessment. These neurobehavioral profiles in infants have been associated with prenatal exposures (prenatal
drugs21,22 and perfluorooctanoic acid23), birth outcomes (gestational age and birth weight21), and with behavioral
and cognitive outcomes in childhood21,22,24. Poorer performance on the NNNS has also been shown to be predictive of non-optimal developmental outcomes through early childhood21. Beyond the neurobehavioral and medical assessments, molecular biomarkers may provide insights into how the environment and experiences of the
preterm newborn are internalized and may hold additional value as predictive tools useful in risk stratification.
Epigenetics refers to mitotically and meiotically heritable changes in gene expression potential that are not
explained by changes in DNA sequence. The most thoroughly studied epigenetic mechanism is DNA methylation
(DNAm), particularly in the context of cytosine-phosphate-guanine (CpG) motifs and islands. These methylation
marks can be inherited across cell divisions, established in-utero and/or affected by the environment throughout life, thus representing a truly integrated measure of exposure and disease susceptibility. In preterm infants,
variability in DNAm of candidate genes have been related to medical complications such as sepsis25, pain related
stress26,27, medical and neurobehavioral risk28,29, and as a potential moderator of NICU environment stress on
serotonergic tone and temperament30. We have also used an epigenome-wide scan of DNAm in the placenta to
demonstrate relationships between methylation of the FHIT and ANDKR11 genes, which had been previously
linked to neurodevelopmental and behavioral outcomes, and performance on the NNNS attention scale in a
cohort of term newborns31. Additionally, DNAm can be used to estimate epigenetic age, which is thought to be a
marker of underlying biological aging32. In children and adolescents, epigenetic age acceleration has been associated with physical development33, pubertal development, internalization and thought problems34, and increased
cortisol production34,35. These studies have begun to elucidate the potential role for epigenetic aging in developmental processes but has not been thoroughly studied in relation to neonatal neurobehavioral responses.
Incorporating molecular biomarkers, such as DNAm and epigenetic age, with performance measures may
improve long-term predictions of health outcomes in preterm infants. Before this can be done, it is important to
demonstrate whether variability in DNAm and epigenetic age, measured from accessible tissues, are associated
with behavioral measures in newborns. In this study, we hypothesized that infants with the most atypical or optimal neurobehavioral profiles, measured via the NNNS, will exhibit unique patterns of DNAm. In a U.S. multisite
cohort of infants born less than 30 weeks PMA, we profiled genome-wide DNAm from buccal swab samples using
the Illumina MethylationEPIC array platform. We estimated epigenetic age and tested for differences in epigenetic age and in DNAm among infants with neurobehavioral profiles, ranging from most optimal to atypical, as
determined via NNNS latent profile classification.

Methods

Study Population. The Neonatal Neurobehavior and Outcomes in Very Preterm Infants (NOVI) Study was
conducted at 9 university-affiliated NICUs in Providence, RI, Grand Rapids, MI, Kansas City, MO, Honolulu, HI,
Winston-Salem, NC, and Torrance and Long Beach CA from April 2014 through June 2016. These NICUs were
also Vermont Oxford Network (VON) participants. All participating mothers provided written informed consent.
Enrollment and consent procedures for this study were approved by the institutional review boards of Women
and Infants Hospital, Spectrum Health, Children’s Mercy Office of Research Integrity, Wake Forest University
Health Sciences, John F. Wolf, MD Human Subjects Committee at Los Angeles BioMed, Emory University and
Western Institutional Review Board (WIRB); all methods employed in the study were performed in accordance
with the relevant guidelines and regulations. Eligibility was determined based on the following inclusion criteria:
(1) birth at <30 weeks’ gestation; (2) parental ability to read and speak English, Spanish, Japanese, or Chinese;
and (3) residence within 3 hours of the NICU and follow-up clinic. Infants were excluded if their medical record
indicated presence of a major congenital anomaly, including central nervous system, cardiovascular, gastrointestinal, genitourinary, chromosomal, and nonspecific anomalies36. Parents of eligible infants were invited to
participate in the study at 31–32 weeks PMA, or when survival to discharge was determined to be likely by the
attending neonatologist. Demographic variables, including infant gender, race, ethnicity, maternal education and
partner status were collected from the maternal interview. Socioeconomic status (SES) was assessed using the
Hollingshead Index, with Hollingshead level V indicating low SES37. Neonatal medical variables including birthweight, gestational age, length of NICU stay, weight at discharge, and gestational age at discharge were abstracted
from medical records. Overall, 709 infants were enrolled, 679 from whom complete neurobehavioral assessment
data were obtained, and buccal cells were collected on 624 of these infants for epigenomic screening.
NICU Network Neurobehavioral Scale (NNNS).

Neonatal neurobehavior was assessed using the
NNNS. The NNNS is a 20–30 minute standardized procedure that includes measures of active and passive tone,
primitive reflexes, items that reflect physical maturity, social and behavioral functioning including visual and
auditory tracking, cuddling and soothability, and a checklist of stress signs organized by organ system38. The
NNNS was administered during the week of NICU discharge (+/− 3 days) by site examiners who were trained
and certified by a central NOVI NNNS trainer. The exam was conducted 45 minutes prior to a scheduled feeding
or routine care in order to maximize alertness and avoid disrupting NICU routines that facilitate sleep patterns.
Individual items were converted to 12 summary scores: attention, handling, self-regulation, arousal, excitability,
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lethargy, hypertonicity, hypotonicity, non-optimal reflexes, asymmetric reflexes, quality of movement and stress
abstinence. A higher summary score does not necessarily reflect better performance, but instead more of the
construct. Summary scores were converted to NNNS profiles, which are mutually exclusive, discrete categories
representing the infant’s pattern of performance across the summary scores, and which have been shown to be
related to future behavioral and cognitive performance21,22,24.

DNA Methylation (DNAm) Analysis. Genomic DNA was extracted from buccal swab samples, collected
near term-equivalent age, using the Isohelix Buccal Swab system (Boca Scientific), quantified using the Quibit
Fluorometer (Thermo Fisher, Waltham, MA, USA) and aliquoted into a standardized concentration for subsequent analyses. DNA samples were plated randomly across 96-well plates and provided to the Emory University
Integrated Genomics Core for bisulfite modification using the EZ DNA Methylation Kit (Zymo Research, Irvine,
CA), and subsequent assessment of genome-wide DNAm using the Illumina MethylationEPIC Beadarray
(Illumina, San Diego, CA) following standardized methods based on the manufacturer’s protocol. Samples with
more than 5% of probes yielding detection p-values > 1.0E-5 (74 samples), with mismatch between reported and
predicted sex (7 samples), or incomplete covariate data (7 samples) were excluded. Additionally, probes with
median detection p-values < 0.05 were excluded. Array data were normalized via functional normalization, then
standardized across Type-I and Type-II probe designs with beta-mixture quantile normalization39. Probes that
measured methylation on the X and Y chromosomes, probes that had single nucleotide polymorphisms (SNP)
within the binding region, that could cross-hybridize to other regions of the genome40, or probes that had low
variability (range of beta-values < 0.05)41 were excluded. After exclusions, 690,781 probes were available from
536 samples for this study. We used gaphunter to flag probes that had outliers or distributional issues that may
be related to genetic effects on DNAm measurement42. These data are accessible through NCBI Gene Expression
Omnibus (GEO) via accession series GSE128821.
Estimate of Epigenetic Age.

We estimated epigenetic age using the online (https://horvath.genetics.ucla.
edu/html/dnamage/) [Accessed 01/15/2019] epigenetic clock calculator43. This method utilizes DNAm levels at
previously identified CpGs that are predictive of chronological age and has been shown to be highly accurate
across a wide range of different cell and tissue types32. This clock also calculates two measures of age acceleration:
the difference between epigenetic and chronological age, and the residuals when epigenetic age is regressed on
chronological age in a linear model. We investigated the age acceleration residuals and epigenetic age in this study.

Estimates of Tissue Heterogeneity. DNAm differs between cell-types, and cellular heterogeneity presents a likely source of confounding in epigenome-wide association studies of mixed cell samples44. Thus, we
estimated the proportions of epithelial, fibroblast, and immune cells (including B-cells, natural killers, CD4+
T-cells, CD8+ T-cells, monocytes, neutrophils, and eosinophils) in our cheek swab samples using reference
methylomes45. For 95% of our samples, epithelial cells made up 95.7% of the cells (Supplemental Fig. 1), while
immune cells made up the majority of the remaining cell types. Due to very strong inverse correlations between
immune cell proportions and epithelial cell proportions (Supplemental Fig. 2), we adjusted for cellular heterogeneity by including the proportions of epithelial cells as covariates in the statistical models.
Statistical Analyses. Latent profile analysis (LPA, Mplus version 8.1) was used to group infants into mutu-

ally exclusive categories using 12 NNNS summary scores based on previous work21. Membership in categorical
latent profiles that represent heterogeneous subgroups was inferred from the 12 NNNS variables. LPA models
with different numbers of profiles were fitted. We identified the model containing the optimal number of profiles
using criteria outlined by Nylund et al.46. Determination of the best model fit was assessed via Bayesian information criteria (BIC) adjusted for sample size, whereby the smallest BIC value indicates the best fit as well as minimization of cross classification probabilities, the bootstrapped likelihood ratio test, and the number of cases in each
profile. As the number of profiles increased from 2 to 6, the sample-size adjusted BIC values decreased, suggesting
improvement in the goodness of fit (Supplemental Table 1). Infants in Profile 6 had a pattern of responses (lowest
scores for attention, self-regulation and quality of movement, average scores for lethargy, hypotonicity, nonoptimal reflexes and asymmetric reflexes, combined with the highest scores for arousal, excitability, hypertonicity
and the most stress abstinence) that was consistent with a latent profile identified by Liu et al. (2010) that had the
most extreme negative scores and was most predictive of nonoptimal developmental outcomes in childhood21.
Whereas infants in Profile 1 exhibited the most optimal responses, and provided the greatest contrast to Profile 6,
thus we focused on these two profiles for the EWAS and epigenetic age analyses.
Statistical analyses of epigenomic data were performed in R version 3.5. We tested for differences in epigenetic
age and age acceleration between the atypical NNNS profile (Profile 6) and optimal NNNS profile (Profile 1)
versus those in the other NNNS profiles using robust linear models via the MASS package. Standard errors and
p-values for robust regressions were estimated using White’s sandwich estimator to protect against potential heteroscedasticity. Epigenetic age and age acceleration were included as continuous dependent variables, the NNNS
profiles were included as a three-level factor for the independent variable, while adjusting for sex, recruitment
site, and cellular heterogeneity. The epigenome-wide association study was performed with robust linear regressions for each CpG site that passed QC, regressing methylation beta-values (dependent variable) on the NNNS
profiles (independent variable), while adjusting for sex, PMA, and proportions of epithelial cells and fibroblasts.
QQ-plots and Manhattan plots were produced using the qqman package. To account for multiple testing, we
implemented a false discovery rate (FDR) and considered those associations that were within a 10% FDR to be
statistically significant. We report all results from models that yielded suggestive associations (p-value < 0.0001)
in the Supplemental Materials.
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Figure 1. Patterns of NNNS z-scores across individual assessments for all six latent profiles among all NOVI
infants that were assessed for the NNNS (N = 679); Profile 6 represents the atypical profile (black) and Profile 1
represents the optimal profile (green).

Profiles
Assessment

1 (n = 62)

2 (n = 176)

3 (n = 61)

4 (n = 83)

5 (n = 118)

6 (n = 36)

ANOVA
p-val.

Attention

7.27 (1.14)

5.04 (1.22)

4.89 (0.90)

6.04 (1.18)

4.43 (1.36)

4.36 (1.25)

<0.001

Handling

0.37 (0.25)

0.29 (0.22)

0.61 (0.25)

0.55 (0.22)

0.37 (0.26)

0.62 (0.27)

<0.001

Quality of Movement

5.06 (0.55)

4.89 (0.45)

4.9 (0.59)

4.58 (0.58)

4.23 (0.49)

3.4 (0.64)

<0.001

Self Regulation

6.69 (0.60)

5.82 (0.45)

5.04 (0.53)

6.09 (0.58)

5.21 (0.51)

4.44 (0.72)

<0.001

Non-Optimal Reflexes

4.18 (1.61)

4.83 (1.52)

4.84 (1.67)

4.1 (1.50)

7.47 (1.70)

6.22 (1.93)

<0.001

Stress Abstinence

0.11 (0.06)

0.09 (0.06)

0.14 (0.07)

0.17 (0.06)

0.16 (0.06)

0.22 (0.08)

<0.001

Arousal

3.18 (0.48)

3.55 (0.37)

4.59 (0.51)

3.91 (0.50)

3.47 (0.50)

4.61 (0.51)

<0.001

Hypertonicity

0.34 (0.75)

0.27 (0.55)

0.8 (1.15)

0.25 (0.49)

0.23 (0.53)

0.97 (1.18)

<0.001

Hypotonicity

0.05 (0.22)

0.15 (0.36)

0.13 (0.39)

0.06 (0.29)

0.52 (0.72)

0.25 (0.44)

<0.001

Asymmetrical Reflexes

1.69 (1.52)

0.43 (0.73)

0.25 (0.54)

2.05 (1.51)

0.94 (1.15)

0.97 (1.44)

<0.001

Excitability

1.42 (1.15)

1.16 (0.93)

4.77 (1.27)

2.52 (1.35)

2.18 (1.13)

7.22 (1.61)

<0.001

Lethargy

3.77 (1.58)

4.8 (1.87)

3.64 (1.53)

3.17 (1.58)

6.17 (2.15)

3.97 (1.92)

<0.001

Table 1. Means and standard errors of individual NNNS assessment scores across the NNNS profile groupings
identified by LPA (N = 536). ANOVA: analysis of variance, LPA: latent profile analysis, NNNS: NICU network
neurobehavioral scale.

We performed sensitivity analyses to examine the impacts of other potential confounders on the associations
between NNNS profiles and DNAm. For these analyses, we included additional variables in the linear models, and
compared the parameter estimates before and after these additional adjustments. We assessed the confounding
effects of sample plate as a batch variable (7-level factor), maternal socioeconomic status (2-level factor), maternal educational attainment (2-level factor), proportions of fibroblasts and immune cells (B-cells, natural killers,
CD4+ T-cells, CD8+ T-cells, monocytes, neutrophils, and eosinophils), race (white, black, Asian, Hawaiian/
Pacific Islander, and other), and birth weight (grams).
To gain insights into the biological functions of the NNNS-associated CpG sites, we performed
over-representation analyses with ConsensusPathDB (CPDB)47,48. We utilized CPDB to examine our gene
lists for enrichment with neighborhood-based entity sets (NESTs) with a radius of one, pathway-based gene
sets from KEGG, Biocarta, and Reactome with minimum overlap with our gene-set of 2, and gene-ontology
(GO) terms. Over-representation results within a 10% FDR were determined to be statistically significant. For
over-representation analyses, we utilized a gene-list containing the genes annotated to the top 250 CpG sites
from the EWAS that were associated with the atypical NNNS profile. We also aimed to examine whether our
NNNS-associated CpGs were within genes that have been linked with phenotypes related to neurodevelopment
or neurodegeneration. Thus, we annotated the top 250 CpGs with traits that have been linked to genes via the
NHGRI-EBI genome-wide association study catalog (GWAS catalog)49.

Results

Study Population and NNNS Profile Results.

We identified six distinct NNNS profiles representing
groups of infants with similar neurobehavioral responses (Fig. 1 and Table 1); two of these profiles stood out as
particularly distinctive. Infants in Profile 1 had the most optimal performance, with the best attention and regulations scores, an average requirement for handling, typical motor tone and movement, and few signs of stress.
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Sample Characteristics

Profiles 2,3,4,5
(N = 438)

Profile 1 (Optimal)
(N = 62)

Profile 6 (Atypical)
(N = 36)

Infant Gender: Male

55.3% (242/438)

56.5% (35/62)

61.1% (22/36)

Recruitment Site:
WIH

19.4% (85/438)

3.2% (2/62)

19.4% (7/36)

SHD

22.6% (99/438)

1.6% (1/62)

0.0% (0/36)

KMC

16.0% (70/438)

17.7% (11/62)

19.4% (7/36)

CMH*

14.8% (65/438)

8.1% (5/62)

0.0% (0/36)

WFU*

14.6% (64/438)

67.7% (42/62)

22.2% (8/36)

LAB*

12.6% (55/438)

1.6% (1/62)

38.9% (14/36)

38.930 ± 3.150

39.415 ± 4.012

40.210 ± 3.462

PMA at Buccal Collection (weeks)
PMA at Birth (weeks)

27.091 ± 1.881

26.756 ± 1.954

26.452 ± 2.154

Birth Weight (grams)

969.0 ± 281.4

903.8 ± 265.0

861.9 ± 291.4

Maternal Age at childbirth (years)

29.171 ± 6.297

29.095 ± 6.972

27.972 ± 6.396

Maternal Smoking During Pregnancy

16.3% (71/436)

14.8% (9/61)

8.3% (3/36)

Education: less than High School/GED

14.6% (62/426)

6.5% (4/62)

22.2% (8/36)

Low SES

8.2% (35/427)

4.8% (3/62)

16.7% (6/36)

Maternal Race:
White

55.0% (236/429)

52.5% (32/61)

27.8% (10/36)

Black

21.9% (94/429)

29.5% (18/61)

19.4% (7/36)

Asian

7.0% (30/429)

9.8% (6/61)

11.1% (4/36)

Hawaiian or Pacific Islander

6.8% (29/429)

6.6% (4/61)

13.9% (5/36)

Other

9.3% (40/429)

1.6% (1/61)

27.8% (10/36)

Table 2. Means ± standard deviations (continuous) or percentages and frequencies (categorical) of covariates
by NNNS profile groupings. PMA: Postmenstrual Age, SES: socioeconomic status, GED: General Equivalency
Diploma, NNNS: NICU network neurobehavioral scale, *enrolled from 2 university-affiliated NICUs.

Infants in Profile 6 showed atypical performance with poor attention, a substantial requirement for handling, poor
regulation, exceptionally high arousal and excitability, hypertonia, poor quality of movement, and substantial signs
of stress. Thus, Profile 1 represents an optimal profile characterized by generally positive, well-modulated neurobehavioral responses, while Profile 6 represents infants with atypical neurobehavioral responses. These findings are
similar to profiles observed previously by others21 and in our own research29. To limit the number of tests being
performed, the current study focused on the most optimal (Profile 1) and atypical (Profile 6) profiles, while using
the combination of Profiles 2–5 as the referent category in downstream analyses. Average PMA at birth, PMA at
buccal cell collection, and maternal age did not substantially differ between the different NNNS profile groupings
(Table 2). On the other hand, we did find that a larger proportion of infants with atypical profiles had caregivers
with lower socioeconomic status (SES) (16.7%) and lower educational attainment (22.2%), compared to those in
the optimal group (4.8% and 6.5% respectively). We also observed significant differences in NNNS profile assignment by recruitment site, and thus recruitment site was controlled for in all downstream analyses.

Epigenetic Age and Age Acceleration Associations with NNNS Profiles. Epigenetic age negatively
correlated with gestational age at birth (R2 = 0.06, p-value < 0.0001), but positively correlated with age since birth
(R2 = 0.15, p-value < 0.0001) and PMA (R2 = 0.14, p-value < 0.0001) (Supplemental Fig. 3). In a linear model
with epigenetic age regressed on both gestational age at birth and PMA at exam date, the relationship with PMA
remained strong while the associations with gestational age was heavily attenuated. Thus, PMA appeared to be
the appropriate age variable to include in models when testing for age acceleration. We examined differences in
epigenetic age and age acceleration that associated with the optimal (n = 62) and atypical (n = 36) NNNS profiles,
by comparing them to the rest of the NOVI infants (n = 438). We found that the infants in the optimal profile
tended to have significantly older epigenetic age (β1 = 0.201, p-value = 0.026) whereas the atypical profile exhibited no difference in epigenetic age (β1 = −0.022, p-value = 0.84) when compared to the rest of the NOVI infants
(Fig. 2A). However, age acceleration did not significantly differ when comparing the optimal or atypical profiles
to the rest of the NOVI infants (Fig. 2B). These models were adjusted for sex, recruitment site, postmenstrual age,
and estimated proportions of epithelial cells and fibroblast cells.
Epigenome-Wide Association Study of NNNS Profiles.

We then performed an EWAS of these two
NNNS profiles to examine whether underlying patterns of epigenetic regulation measured in buccal cells differed among infants within the NNNS profiles. We report all results for the EWAS of the optimal and atypical
NNNS profiles that yielded associations with p-values < 0.0001 in the Supplemental Materials (Supplemental
Tables 2, 3, respectively). Thirty CpGs were differentially methylated (at a 10% FDR) with either of the NNNS
profile groupings (Table 3). The only CpG associated with the optimal NNNS profile was cg03046148. Infants
with this profile had higher DNAm levels (β1 = 0.0145, p-value = 1.43E-07). On the other hand, we identified 29
epigenetic loci that were associated with the atypical NNNS profile after FDR-adjustment, which were located
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Figure 2. Relationships between epigenetic age (A) and age acceleration (B) with NNNS profile groupings;
the x-axis includes the optimal profile (Profile 1), the atypical profile (Profile 6), as well as other NOVI infants
(Profiles 2–5), while the y-axis represents epigenetic age and age acceleration after adjusting for sex, recruitment
site, and cell-mixture.
throughout the genome (Fig. 3). The most statistically significant relationship was observed at cg23172057
(β1 = 0.0299, p-value = 5.43E-08) which is within the body of the coagulation factor X (F10) gene. The magnitudes of effect among the FDR-significant hits tended to be small, with differential methylation ranging between
0.42% to 6.53% lower and between 0.31% to 10.61% higher methylation among the atypical NNNS group. The
CpGs with the largest magnitudes of association among the FDR-significant hits were observed at cg14792155
(β1 = 0.1061, p-value = 4.04E-06) which is within the body of the phospholipase A2 group IVE (PLA2G4E) gene
and at cg07850633 (β1 = −0.0653, p-value = 1.49E-06) which is within the body of the MACRO domain containing 2 (MACROD2) gene.
Based on observed differences in SES, maternal educational attainment, and maternal smoking during pregnancy among those with optimal or atypical NNNS profiles, as well as hypothesized potential confounding effects
of batch (sample plate), immune cell proportions, race, and birth weight, we performed a sensitivity analyses with
additional adjustment for these variables in our linear models. Additional adjustments for these potential confounders did not alter the observed associations between DNAm and atypical NNNS profiles (Supplemental Fig. 4).

Functional and Phenotype Enrichment.

We then used enrichment analyses to examine whether the
genes annotated to NNNS-associated CpGs have a higher than expected proportion of genes that interact with
each other, are involved in known biological pathways, or are linked to specific gene ontology terms. For this analysis, we utilized the top 250 CpGs that associated with the atypical NNNS profiles. We found that this gene-set
was enriched for one neighborhood-based entity sets (NESTs) (FDR q-value = 0.031), centered on the CRIM1
gene which has physical interactions with four genes, two of which were also in our gene-set: ATXN7 and MEGF6.
We also identified 54 pathway-based gene-sets (Supplemental Table 4) many of which may be relevant for neurodevelopment, including synaptic activity, neurotransmitters, and nerve growth factors (Table 4). Additionally,
our gene-set was enriched for nine gene-ontology (G0) terms (Supplemental Table 5), including neuron projection (FDR q-value = 0.0371) and neuron part (FDR q-value = 0.0505). Multiple pathway and GO-term enrichments included GRIK3, TRIM9, and PLA2G4E, genes that were annotated to CpGs that yielded FDR-significant
associations from our EWAS.
Since only one of our CpGs yielded an association with the NNNS profiles at a stricter threshold of statistical
significance (5% FDR), we focused on this CpG for follow-up analyses examining whether the atypical NNNS
profile exhibited differential methylation with each of the NNNS profiles. We regressed cg23172057 DNAm levels on a six level factor variable (using the atypical profile as the referent) while adjusting for sex, site, PMA,
proportions of epithelial cells, and proportions of fibroblasts. The atypical NNNS profile exhibited significantly
higher DNAm (p-values < 0.05) than each of the NNNS profiles, with the most substantial differential DNAm
when comparing to Profile 3 (4.0% lower; p-value = 1.242E-07) and Profile 5 (3.4% lower; p-value = 9.76E-08)
(Supplemental Fig. 5).

CpG Annotation.

Relatively few genes have been studied for their associations with neonatal neurobehavioral characteristics. However, it is plausible that the genes that are linked to cognition, neurobehavior, or
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CpG Annotations

Optimal NNNS Profile

Atypical NNNS Profile

CpG

Location

Gene

β1

P-value

β1

cg25755851

chr1:9335794

—

−0.013

1.89E-01

−0.032

2.53E-06*

cg22960767

chr1:37422679

GRIK3 (Body)

0.022

1.39E-02

0.036

3.55E-06*

−0.001

7.00E-01

−0.004

7.38E-07*

0.001

8.50E-01

0.034

2.48E-06*

cg26057754

chr1:183774231

RGL1 (Body)

cg23264395

chr1:207096239

FCMR (TSS1500)

P-value

cg01479768

chr2:731298

—

−0.006

6.91E-01

0.045

2.20E-06*

cg08902894

chr2:3142407

—

0.002

7.22E-01

0.029

1.10E-07*

cg05696361

chr2:107108978

—

0.003

7.78E-01

0.048

2.79E-07*

cg17505883

chr2:130552292

—

0.006

2.59E-01

0.021

1.94E-06*

cg03046148

chr3:13695666

LOC285375 (Body)

0.015

1.43E-07*

0.003

4.56E-01

cg07193729

chr4:176031198

—

0.006

5.03E-02

0.014

3.07E-07*

−0.001

9.31E-01

0.037

9.98E-07*

0.001

9.23E-01

0.028

4.29E-07*

cg02236672

chr5:132449216

—

cg00210856

chr5:158466226

EBF1 (Body)

cg02057469

chr7:95951623

SLC25A13 (TSS200)

−0.001

1.19E-01

−0.004

3.05E-06*

cg04524088

chr7:127847835

MIR129-1 (TSS200)

−0.016

1.68E-01

0.045

2.27E-06*

cg17287134

chr7:154959606

—

−0.008

4.52E-01

0.040

1.01E-06*

cg21672855

chr8:135614777

ZFAT (Body)

−0.002

1.73E-01

0.005

1.71E-06*

cg14632902

chr9:139017648

—

0.012

1.91E-02

0.026

3.49E-06*

cg06846137

chr10:131682939

EBF3 (Body)

0.004

4.20E-01

0.019

1.36E-06*

cg13716458

chr11:28997975

—

0.006

6.38E-02

0.020

5.51E-07*

cg07895260

chr12:55537168

—

−0.001

9.37E-01

0.034

3.19E-06*

−0.001

9.20E-01

0.044

2.93E-06*

0.010

1.55E-01

0.030

5.43E-08**

cg27361636

chr12:120502417

BICDL1 (Body)

cg23172057

chr13:113800351

F10 (Body)

cg11042421

chr14:42881184

—

0.006

4.29E-02

0.015

2.71E-06*

cg14354244

chr14:51446038

TRIM9 (Body)

0.006

5.04E-01

0.034

3.66E-06*

cg03444659

chr14:94834215

SERPINA2 (TSS1500)

−0.002

7.14E-01

0.015

1.43E-06*

cg14792155

chr15:42289618

PLA2G4E (Body)

−0.007

7.50E-01

0.106

4.04E-06*

cg02187389

chr16:1247777

CACNA1H (Body)

0.000

9.97E-01

0.024

7.96E-07*

cg02234314

chr19:55986224

ZNF628 (TSS1500)

0.003

7.85E-01

0.059

2.08E-06*

cg07850633

chr20:15795880

MACROD2 (Body)

0.017

3.49E-01

−0.065

1.49E-06*

cg09772858

chr22:49549729

—

0.006

4.15E-01

0.030

2.52E-06*

Table 3. Epigenome-wide association study results for CpG sites that yielded associations within a 5% (**)
or 10% (*) FDR for either the optimal or atypical NNNS profile groupings; beta coefficients (β1) represent the
mean difference in methylation proportion when comparing the optimal or atypical NNNS profiles to the
rest of the NOVI sample. CpG = cytosine-phosphate-guanine methylation site, FDR = False Discover Rate,
NNNS = NICU Network Neurobehavioral Scale; For CpGs with no annotated genes, we annotated this with the
nearest genes within 2500 bp of the CpG.

Figure 3. Manhattan plot of epigenetic loci associated with the atypical NNNS profile; the x-axis represents
the genomic location of the individual probes and the y-axis represents the -log10(p-values) from related to the
Atypical NNNS profile, adjusted for sex, recruitment site, postmenstrual age, and cell-mixture; gene annotations
for the CpGs yielding associations within the 10% FDR threshold have been added to the plot.

neurodegeneration at other life stages may also be important in neurobehavioral function in very early life. We
identified phenotypes or traits that have been associated with the genes annotated to the CpGs associated with
NNNS profiles at a 10% FDR (Table 5). Importantly, Table 5 also presents 7 of the 11 genes that have been linked
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Pathway ID

Pathway Description

Total Genes

NNNS-Associated Genes

P-val.

path:hsa04724

Glutamatergic synapse - Homo sapiens
(human)

114

PLCB1; GRIK3; PRKCB;
PLA2G4E; ADCY3

FDR Q-val.

0.0020

0.026

R-HSA-112314

Neurotransmitter receptors and
postsynaptic signal transmission

152

PLCB1; GRIK3; AP2A2; PRKCB;
ADCY3

0.0069

0.040

R-HSA-416993

Trafficking of GluR2-containing AMPA
receptors

17

PRKCB; AP2A2

0.0077

0.040

R-HSA-112316

Neuronal System

367

PLCB1; PRKCB; PTPRS; KCNK9;
ADCY3; GRIK3; AP2A2; KCNA3

0.0082

0.041

ngfpathway

nerve growth factor pathway (ngf)

18

PLCG1; NGFR

0.0086

0.043

Table 4. Pathways involved in neurodevelopment and/or neuronal activity that were significantly (FDR < 0.10)
over-represented among the genes annotated to the top 250 CpGs that associated with the Atypical NNNS
profile. NNNS = NICU Network Neurobehavioral Scale; FDR = False Discover Rate.

Gene

N

Trait Types

Specific Cognitive, Neurobehavioral or
Neurological Traits

F10

4

Hematopoietic

—

EBF1

34

Hematopoietic, Cardiovascular, Immune, Growth &
Metabolism, Birth Outcomes, Neurobehavior, Cognition

Psychosocial stress measurement, cognitive
impairment, cognitive decline measurement

RGL1

7

Attention deficit hyperactivity disorder, conduct
Neurobehavior, Cardiovascular, Environmental Exposures,
disorder, schizophrenia, response to antipsychotic
Hematopoietic, Liver
drug, response to antidepressant

CACNA1H

1

Hematopoietic

—

EBF3

3

Cancer, Bone, Neurological, Sleep

Peripheral neuropathy

SERPINA2

6

Growth, Respiratory, Cardiovascular, Hematopoietic

—

MACROD2

31

Neurobehavior, Neurological, Liver, Growth &
Metabolism, Hematopoietic, Bone, Birth Outcomes,
Respiratory, Cardiovascular, Environmental Exposures,
Bone, Immune

Autism, eating disorder, brain connectivity
measurement, sporadic amyotrophic lateral
sclerosis, prion disease, mood disorder

ZFAT

12

Growth & Metabolism, Cardiovascular, Cognitive,
Environmental Exposures, Immune, Respiratory, Other

Self-reported educational attainment

GRIK3

6

Neurobehavior, Immune, Respiratory, Environmental
Exposures

Unipolar depression, neuroticism measurement,
depressive symptom

TRIM9

5

Growth & Metabolism, Neurobehavior, Immune, Cancer

Psychosis

PLA2G4E

1

Environmental Exposures

—

Table 5. Genes annotated to our atypical NNNS-associated CpGs that have been linked to traits from the
GWASdb. N = number of traits linked to that gene.

to neurobehavioral or neurodegenerative traits including autism, attention deficit hyperactivity disorder, cognitive impairment, depression, and psychosis.

Discussion

Our study focused on a comparison of neurobehavioral profiles with DNAm levels and epigenetic age. We used
the NNNS summary scores to identify a group of infants with an optimal profile and a group with an atypical profile, which are similar to what has been observed previously by others and in our own research including preterm
infants21,24,29. The infants in the atypical profile had the lowest scores for attention, self-regulation and quality of
movement, average scores for lethargy, hypotonicity, nonoptimal reflexes and asymmetric reflexes, combined with
the highest scores for arousal, excitability, hypertonicity and the most stress abstinence. This pattern of NNNS
responses in our atypical profile was consistent with a latent profile identified by Liu et al. (2010) that was most
predictive of non-optimal developmental outcomes in childhood21. Whereas the infants in our optimal profiles
had the most positive responses across the NNNS and provided the greatest contrast to compare with the atypical
profile. We found that very premature infants in the NOVI cohort with an optimal neurobehavioral profile had
older epigenetic age than other very premature infants. We also found that age acceleration followed a stepwise
trend in which infants with the optimal profile had the greatest age acceleration and infants with the atypical
profile had the least age acceleration, though this finding was not statistically significant and may be driven by the
differences in age at exam across the NNNS profile groups. Epigenetic age is an estimate of the state of underlying
physiologic processes, as they relate to biological development and maintenance32, and has been studied in the
context of health conditions that are linked to the aging process, including frailty50, physical capability51,52, cognitive fitness51, decreased cognitive function and neuropathologies in persons suffering from Alzheimer’s Disease53,
and all-cause mortality54. In these studies, age acceleration is analogous to biological decline.
These relationships may differ in early life, however, when children are still undergoing substantial growth
and development, and it is unclear whether accelerated aging would be expected to be associated with positive
or negative developmental characteristics. In fact, if epigenetic aging captures, or is a surrogate for, the activity of
developmental processes, epigenetic age acceleration throughout early development may be an indicator through
Scientific Reports |

(2019) 9:6322 | https://doi.org/10.1038/s41598-019-42654-4

8

www.nature.com/scientificreports/

www.nature.com/scientificreports

which to track developmental “catch-up”. An epigenetic clock has also been developed to estimate epigenetic gestational age acceleration from cord blood DNAm55. Interestingly, gestational age acceleration has been associated
with reduced infant respiratory morbidities56, which provides some evidence that older epigenetic age in infancy
may correlate with positive developmental characteristics. In our analysis, we did not observe a significant relationships between age acceleration with the optimal or atypical NNNS profiles.
A handful of studies have examined the relationships between epigenetic age and development in children.
For instance, epigenetic age positively correlates with measures of physical development such as fat mass, height,
Tanner stages33, pubertal development, internalization and thought problems34, and increased cortisol34,35. One
study observed interrelationships between age acceleration, cortisol production, and hippocampal volume,
potentially linking hypothalamic-pituitary-adrenal (HPA) axis activity, neuroanatomy, and epigenetic aging35.
This topic requires additional study and should ideally be investigated in a longitudinal manner, in which both
epigenetic age and neurobehavioral assessments are tracked in parallel through early-life development.
Though the infants with the atypical NNNS profile did not have significantly different epigenetic age from the
other NOVI infants, we did identify multiple differentially methylated CpGs throughout the genome that were
associated with the group with atypical neurobehavioral responses. Our EWAS revealed 29 epigenetic loci that
significantly associated (<10% FDR) with the atypical profile. The CpG with the smallest p-value was annotated
to the (cg2317205) F10 gene and was the only CpG that yielded an association at a stricter threshold for statistical
significance (<5% FDR). We also found that the average DNAm at cg23172057 was significantly higher among
the atypical NNNS profile even when comparing to each of the 5 other NNNS profiles individually. Thus, this CpG
holds promise as a potential marker of problematic neurobehavioral responses in preterm infants. However, the
gene that this CpG is annotated to (F10) has not been associated with behavioral or cognitive function. Instead,
F10 is involved in the blood coagulation cascade and primarily associated with hematologic disorders57. On the
other hand, the other 28 CpGs only met a 10% FDR threshold of statistical significance, and likely do include
some false positives, but a number of the genes annotated to these CpGs have been linked to cognition or educational attainment (EBF1 & ZFAT), and neurobehavioral or neurological disorders in GWAS studies (EBF1, RGL1,
EBF3, MACROD2, GRIK3, and TRIM9). We also found that the top 250 CpGs from this analysis were enriched for
genes within pathways involving neurotransmitters and synaptic activity, as well as GO-terms related to neuron
projection and structure. Of particular note, three genes annotated to the FDR-significant CpGs were within these
neuronal-associated GO-terms and pathways: phospholipase A2 group IVE (PLAG2G4E), glutamate ionotropic
receptor kainate type subunit 3 (GRIK3), and tripartite motif containing 9 (TRIM9). The CpG site that yielded
the largest magnitude of association among our statistically significant hits, cg14792155, was within the body of
the PLA2G4E gene. This gene encodes for a calcium-dependent N-acyltransferase; experimental mouse models
have implicated that it likely plays a critical role in endocannabinoid signaling in the nervous system58 and thus
differential regulation of this gene has implications for neurodevelopment and neurodegenerative disorders59. In
human observational studies, placental CpGs within PLA2G4E have been observed to be differentially methylated
in association with extremely preterm births60 and genetic variants within the PLA2G4E gene have been implicated as a potential risk factor for neurodevelopmental problems such as panic disorder61. The protein encoded by
GRIK3 is involved in presynaptic neurotransmission, and has been associated with developmental delay62, schizophrenia63, obsessive-compulsive disorder64, and depression65. The protein encoded by TRIM9 regulates axon
guidance and neural outgrowth66,67, while deletion of TRIM9 has been associated with structural and functional
abnormalities and impaired learning and memory in mice68. The CpG site that yielded the largest statistically
significant inverse association, cg07850633, was within the body of the MACRO domain-containing protein 2
(MACROD2) gene; which has been associated with autism spectrum disorder (ASD)69, though other studies have
yielded potentially contradictory evidence70, autism-like traits71and has been implicated in other neurological
disorders72,73, and temporal lobe volume74. Variants in EBF3, which encode for the early B Cell Factor 3, may
contribute to developmental delay and intellectual impairment75. Genetic variation in the Ral Guanine Nucleotide
Dissociation Stimulator Like 1 (RGL1) gene, has been associated with attention76 and conduct problems among
children with attention deficit hyperactivity disorder77. Additionally, genetic mutations within CACNA1H, which
encodes for a subunit of a voltage gated calcium channel, lead to decreased calcium channel activity in neuronal
cells, and have been linked to ASD78, to epilepsy79, and to amyotrophic lateral sclerosis80. Overall, these findings
suggest that our NNNS-associated epigenetic variations occurred at numerous genomic regions with recognized
roles in neurodevelopmental or neurodegenerative disorders. Interestingly, Sparrow et al. (2016) performed an
EWAS of preterm birth using saliva samples to identify a number of genes that were differentially methylated in
association with preterm birth that are also involved in neuronal function and/or neurobehavioral traits81. Their
findings lead them to speculate that preterm-associated variations in DNAm may contribute to the neural and
behavioral phenotypes that are linked to preterm birth. Thus, differential epigenetic regulation in babies that are
born preterm may provide a link between preterm birth and poorer neurodevelopmental outcomes.
There were some limitations to this study. We used a false discovery rate of 10% to identify significantly differentially methylated CpG sites. Only one of our models yielded an FDR < 5%, and none of the models would
survive Bonferroni adjustment. Thus, it is probable that some of identified epigenetic loci are false-positives. We
encourage additional investigation of infant DNAm, epigenetic age, and neurobehavior to determine whether
similar relationships can be observed in independent populations. There is also the possibility of residual confounding, though our findings were robust to adjustments for numerous potential confounders. We utilized buccal cells as a surrogate tissue to examine the relationships between neurobehavioral profiles and DNAm, as it is
not possible to perform such examinations in the neuronal tissues. However, for studies of children, buccal cell
collection leads to greater compliance82, and evidenced here in our 93% consent rate for parents who gave overall
consent for NOVI. Recent evidence also suggests that buccal samples may be very appropriate for epigenetic analyses of neurodevelopmental outcomes, as they arise from the same germ cell layer as the brain and thus may share
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similar early epigenetic patterning and susceptibility83–85, and have demonstrated DNAm variability associated
with later neurobehavioral outcomes.
We nevertheless remain cautious in the interpretation of these observations in terms of mechanism. These
data were collected and analyzed cross-sectionally, so we cannot infer directionality of the observed relationships
between NNNS profiles with DNAm or epigenetic age. It is notable, however, that the atypical profile observed by
us and others in different populations21,24,29, has also been related to differential DNAm in other tissues29 and predicted developmental outcomes in childhood21. Thus, it is possible that the combination of epigenetic measures
and NNNS profiles may lead to the early identification of which individual children are most at risk for adverse
developmental outcome. Longitudinal studies of epigenomics and neurobehavioral outcomes are needed to establish whether epigenetic variations are detectable prior to the presentation of neurobehavioral impairments, and to
examine whether and how these potential predictors vary throughout early life development.

Conclusions

We found that among very preterm infants (<30 weeks PMA), those with an optimal neurobehavioral profile
had slightly older epigenetic age, while infants with a poorly regulated neurobehavioral profile had differentially
methylated CpGs at multiple genes linked to neural structure, function, or different neurobehavioral or neurodegenerative conditions. These relationships were detected using buccal cell DNAm, building upon the existing
evidence that buccal cells may be a suitable surrogate tissue for studying neurobehavioral conditions in human
observational studies. One CpG within the F10 gene had the strongest association (<5% FDR) with the NNNS,
while three other CpGs (<10% FDR) were within genes yielding multiple levels of evidence for plausible roles
in neurobehavioral health, annotated to PLA2G4E, TRIM9, and GRIK3, all of which were among the significantly enriched GO-terms or neuronal pathways, and linked to neurobehavioral disorders. The combination of
epigenomics and neurobehavior holds promise for a personalized medicine approach to the early detection of
children most at risk for poor developmental outcome.

Data Availability

The microarray data generated and/or analyzed in the current study are available in the NCBI GEO [Accession
series GSE128821]. R codes used for the analyses presented in the paper are available upon request to the corresponding author.
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